EF Hutton analyst Tony Butler downgraded Aravive to Hold from Buy with a price target of $1, down from $10, after the Phase 3 trial of batiraxcept in combination with paclitaxel to treat platinum-resistant ovarian cancer did not meet the primary endpoint of progression-free survival. The firm says its net present values on ovarian cancer for batiraxcept are now eliminated and that the company’s current cash is insufficient at this time to support funding for an additional trial.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARAV: